2521 related articles for article (PubMed ID: 11869664)
21. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
Gordon DH
Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
[TBL] [Abstract][Full Text] [Related]
22. [Bisphosphonates and bone metastases].
Lortholary A; Jadaud E; Berthaud P
Bull Cancer; 1999 Sep; 86(9):732-8. PubMed ID: 10519966
[TBL] [Abstract][Full Text] [Related]
23. Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Major PP; Lipton A; Berenson J; Hortobagyi G
Cancer; 2000 Jan; 88(1):6-14. PubMed ID: 10618600
[TBL] [Abstract][Full Text] [Related]
24. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
[TBL] [Abstract][Full Text] [Related]
25. The role of bisphosphonates in hormone-refractory prostate cancer.
Saad F; Karakiewicz P; Perrotte P
World J Urol; 2005 Feb; 23(1):14-8. PubMed ID: 15666171
[TBL] [Abstract][Full Text] [Related]
26. The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases.
Paterson AH
Cancer; 2000 Jun; 88(12 Suppl):3038-46. PubMed ID: 10898349
[TBL] [Abstract][Full Text] [Related]
27. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.
Hillner BE; Ingle JN; Berenson JR; Janjan NA; Albain KS; Lipton A; Yee G; Biermann JS; Chlebowski RT; Pfister DG
J Clin Oncol; 2000 Mar; 18(6):1378-91. PubMed ID: 10715310
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.
Machado M; Cruz LS; Tannus G; Fonseca M
Clin Ther; 2009 May; 31(5):962-79. PubMed ID: 19539097
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonates: biological response modifiers in breast cancer.
Paterson AH
Clin Breast Cancer; 2002 Aug; 3(3):206-16; discussion 217-8. PubMed ID: 12196279
[TBL] [Abstract][Full Text] [Related]
31. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
Lipton A; Theriault RL; Hortobagyi GN; Simeone J; Knight RD; Mellars K; Reitsma DJ; Heffernan M; Seaman JJ
Cancer; 2000 Mar; 88(5):1082-90. PubMed ID: 10699899
[TBL] [Abstract][Full Text] [Related]
32. Bisphosphonates for osteoporosis in people with cystic fibrosis.
Brenckmann C; Papaioannou A
Cochrane Database Syst Rev; 2001; (4):CD002010. PubMed ID: 11687132
[TBL] [Abstract][Full Text] [Related]
33. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
McKeage K; Plosker GL
Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
[TBL] [Abstract][Full Text] [Related]
34. Bisphosphonates for malignancy-related bone disease: current status, future developments.
Body JJ
Support Care Cancer; 2006 May; 14(5):408-18. PubMed ID: 16450087
[TBL] [Abstract][Full Text] [Related]
35. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Body JJ; Bartl R; Burckhardt P; Delmas PD; Diel IJ; Fleisch H; Kanis JA; Kyle RA; Mundy GR; Paterson AH; Rubens RD
J Clin Oncol; 1998 Dec; 16(12):3890-9. PubMed ID: 9850035
[TBL] [Abstract][Full Text] [Related]
36. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials.
Tripathy D; Body JJ; Bergström B
Clin Ther; 2004 Dec; 26(12):1947-59. PubMed ID: 15823760
[TBL] [Abstract][Full Text] [Related]
37. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.
Coukell AJ; Markham A
Drugs Aging; 1998 Feb; 12(2):149-68. PubMed ID: 9509293
[TBL] [Abstract][Full Text] [Related]
38. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis.
Lopez-Olivo MA; Shah NA; Pratt G; Risser JM; Symanski E; Suarez-Almazor ME
Support Care Cancer; 2012 Nov; 20(11):2985-98. PubMed ID: 22956190
[TBL] [Abstract][Full Text] [Related]
39. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
Coleman RE
Breast Cancer; 2000; 7(4):361-9. PubMed ID: 11114866
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonates: clinical experience.
Coleman RE
Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]